https://www.ascelia.com/sv/mfn_news/ascelia-pharma-presenterar-resultat-fran-orviglance-food-effect-studie-vid-rsna-2022-som-visar-stark-forbattring-av-visualisering-av-levern-bade-med-latt-maltid-och-i-fastande-tillstand/2022-11-30T08:00:00+01:00https://www.ascelia.com/sv/mfn_news/kvartalsrapport-q3-2022-framgangsrik-slutrapportering-i-tva-av-tre-studier-infor-regulatorisk-ansokan/2022-11-04T08:00:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-utokar-sin-ledningsgrupp/2022-10-05T08:30:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-meddelar-framgangsrik-slutrapportering-av-studie-av-orviglance-vid-nedsatt-leverfunktion/2022-09-28T10:30:00+02:00https://www.ascelia.com/sv/mfn_news/halvarsrapport-2022-starka-resultat-fran-orviglance-mateffektstudie/2022-08-18T08:00:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-presenterar-orviglance-mateffektstudie-vid-rsna-2022-konferensen/2022-08-11T07:30:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-utser-despina-georgiadou-hedin-till-ny-cfo/2022-06-20T13:00:00+02:00https://www.ascelia.com/sv/mfn_news/resultat-fran-orviglance-jamforelsestudie-med-gadolinium-presenterad-vid-esgar-2022-konferensen/2022-06-01T14:02:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharmas-andra-amerikanska-patent-for-oncoral-oralt-irinotekan-starker-skyddet-ytterligare/2022-05-31T07:30:00+02:00https://www.ascelia.com/sv/mfn_news/kvartalsrapport-q1-2022-starkt-stod-till-orviglance-fran-vardpersonal/2022-05-11T08:00:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharmas-mateffektstudie-visar-att-orviglances-bildforbattring-av-levern-inte-minskas-av-latt-maltid/2022-05-10T07:30:00+02:00https://www.ascelia.com/sv/mfn_news/kommunike-fran-arsstamma-den-5-maj-2022-i-ascelia-pharma-ab/2022-05-05T12:59:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-publicerar-arsredovisning-for-2021/2022-04-11T12:47:00+02:00https://www.ascelia.com/sv/mfn_news/kallelse-till-arsstamma-i-ascelia-pharma-ab/2022-04-05T22:05:00+02:00https://www.ascelia.com/sv/mfn_news/cfo-kristian-borbos-lamnar-ascelia-pharma/2022-04-01T08:34:00+02:00https://www.ascelia.com/sv/mfn_news/antal-aktier-och-roster-i-ascelia-pharma-ab/2022-03-31T10:20:00+02:00https://www.ascelia.com/sv/mfn_news/ny-oberoende-marknadsundersokning-visar-att-84-av-amerikanska-lakare-sannolikt-kommer-att-anvanda-orviglance-som-kontrastmedel-till-den-avsedda-patientmalgruppen/2022-03-22T07:30:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-har-framgangsrikt-slutfort-orviglance-hepatic-impairment-study/2022-03-11T07:05:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-avbryter-klinisk-verksamhet-i-ryssland/2022-03-07T18:39:00+01:00https://www.ascelia.com/sv/mfn_news/nyemission-och-aterkop-av-c-aktier-for-aktiesparprogram/2022-03-02T14:57:00+01:00https://www.ascelia.com/sv/mfn_news/resultat-fran-orviglance-jamforelsestudie-med-gadolinium-godkant-som-muntlig-presentation-till-esgar-konferensen/2022-02-15T08:41:00+01:00https://www.ascelia.com/sv/mfn_news/kvartalsrapport-q4-2021-starka-resultat-for-orviglance-jamfort-med-ett-gadolinium-kontrastmedel/2022-02-10T08:00:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-erhaller-fda-godkannande-av-ind-ansokan-for-klinisk-studie-med-oncoral/2021-12-16T09:39:00+01:00https://www.ascelia.com/sv/mfn_news/resultat-fran-orviglances-jamforelsestudie-med-gadolinium-presenterade-pa-rsna-2021/2021-12-01T19:39:00+01:00https://www.ascelia.com/sv/mfn_news/valberedningen-utsedd-i-ascelia-pharma-ab-infor-arsstamman-2022/2021-11-30T08:00:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-ab-analyguiden-viktigt-avtal-for-oncoral/2021-11-11T09:29:07+01:00https://www.ascelia.com/sv/mfn_news/kvartalsrapport-q3-2021-oncoral-inleder-kliniskt-samarbete/2021-11-04T08:00:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharmas-mateffektstudie-med-orviglance-framgangsrikt-slutford/2021-10-19T07:30:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-tecknar-kliniskt-samarbetsavtal-med-taiho-oncology-inc-for-utveckling-av-oncoral-i-kombination-med-lonsurf/2021-09-21T07:30:00+02:00https://www.ascelia.com/sv/mfn_news/kvartalsrapport-q2-2021-forbereder-oncoral-for-nasta-niva/2021-08-19T08:00:00+02:00https://www.ascelia.com/sv/mfn_news/covid-19-forlanger-rekryteringsperioden-for-sparkle-studien/2021-08-18T19:10:00+02:00https://www.ascelia.com/sv/mfn_news/abstract-for-orviglance-jamforelsestudie-mot-gadolinium-accepteras-till-varldens-storsta-radiologikonferens-rsna/2021-08-13T07:25:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-far-villkorat-fda-godkannande-for-varumarket-orviglance/2021-08-10T09:31:00+02:00https://www.ascelia.com/sv/mfn_news/kvartalsrapport-q1-2021-usa-kontor-oppnat-infor-lansering/2021-05-12T08:00:00+02:00https://www.ascelia.com/sv/mfn_news/kommunike-fran-arsstamma-den-5-maj-2021-i-ascelia-pharma-ab/2021-05-05T12:56:00+02:00https://www.ascelia.com/sv/mfn_news/antalet-aktier-och-roster-i-ascelia-pharma-ab/2021-04-30T15:15:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-ab-offentliggor-prospekt-avseende-upptagande-till-handel-av-nyemitterade-aktier-pa-nasdaq-stockholm/2021-04-15T16:55:00+02:00https://www.ascelia.com/sv/mfn_news/kommunike-fran-extra-bolagsstamma-i-ascelia-pharma-ab/2021-04-13T11:30:00+02:00https://www.ascelia.com/sv/mfn_news/nyemission-och-aterkop-av-c-aktier-for-aktiesparprogram-2/2021-04-09T16:52:00+02:00https://www.ascelia.com/sv/mfn_news/kallelse-till-arsstamma-i-ascelia-pharma-ab-2/2021-03-31T21:34:00+02:00https://www.ascelia.com/sv/mfn_news/antalet-aktier-och-roster-i-ascelia-pharma-ab-2/2021-03-31T14:00:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-publicerar-arsredovisning-for-2020/2021-03-30T12:30:00+02:00https://www.ascelia.com/sv/mfn_news/kallelse-till-extra-bolagsstamma-i-ascelia-pharma-ab/2021-03-17T23:15:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-har-genomfort-en-riktad-nyemission-om-200-miljoner-kronor/2021-03-17T22:50:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-avser-genomfora-en-riktad-nyemission/2021-03-17T17:31:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-oppnar-kontor-i-usa-som-forberedelse-infor-lansering-av-mangoral/2021-03-02T09:30:00+01:00https://www.ascelia.com/sv/mfn_news/kvartalsrapport-q4-2020-mangoral-visar-stort-diagnostiskt-varde-i-ny-studie/2021-02-16T08:00:00+01:00https://www.ascelia.com/sv/mfn_news/information-avseende-overlatelse-av-aktier-i-ascelia-pharma-ab-fran-cmc-spv/2021-01-14T20:45:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-presenterar-klinisk-utvecklingsplan-for-oncoral-som-en-ny-cellgiftsbehandling/2021-01-12T07:30:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-far-amerikanskt-patent-for-andra-generationens-mangoral/2020-12-15T07:30:00+01:00https://www.ascelia.com/sv/mfn_news/ny-studie-visar-att-mangorals-visualisering-av-lesioner-ar-lika-effektiv-som-gadoliniumbaserat-kontrastmedel/2020-12-02T08:00:00+01:00https://www.ascelia.com/sv/mfn_news/kvartalsrapport-q3-2020-hojt-marknadsestimat-for-mangoral-och-forberedelse-infor-marknadslansering/2020-11-05T08:00:00+01:00https://www.ascelia.com/sv/mfn_news/ema-bekraftar-att-mangoral-ar-berattigat-till-centraliserat-regleringsforfarande-i-eu/2020-11-03T15:30:00+01:00https://www.ascelia.com/sv/mfn_news/det-uppskattade-vardet-pa-mangorals-marknadspotential-hojs-till-500-600-miljoner-usd-per-ar/2020-10-21T08:00:00+02:00https://www.ascelia.com/sv/mfn_news/inbjudan-till-ascelia-pharmas-virtuella-kapitalmarknadsdag/2020-09-30T10:45:00+02:00https://www.ascelia.com/sv/mfn_news/forsta-tillverkning-av-mangoral-i-kommersiell-skala/2020-09-18T08:30:00+02:00https://www.ascelia.com/sv/mfn_news/kvartalsrapport-q2-2020-forsta-deltagaren-till-den-hepatiska-studien/2020-08-20T08:00:00+02:00https://www.ascelia.com/sv/mfn_news/andring-av-antalet-aktier-och-roster-i-ascelia-pharma-ab/2020-07-31T14:00:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-genomfor-en-riktad-nyemission-om-4-697-781-aktier-och-tillfors-cirka-987-msek/2020-06-30T18:30:00+02:00https://www.ascelia.com/sv/mfn_news/presentation-av-ascelia-pharma-pa-abgsc-life-science-summit-day-and-redeye-orphan-drug-day/2020-06-09T12:30:00+02:00https://www.ascelia.com/sv/mfn_news/uppdaterad-tidsplan-for-sparkle-till-foljd-av-covid-19/2020-05-20T18:00:00+02:00https://www.ascelia.com/sv/mfn_news/kvartalsrapport-q1-2020-forsta-patienten-inkluderad-i-fas-3-studien-sparkle/2020-05-13T08:00:00+02:00https://www.ascelia.com/sv/mfn_news/kommunike-fran-arsstamma-den-6-maj-2020-i-ascelia-pharma-ab/2020-05-06T17:00:00+02:00https://www.ascelia.com/sv/mfn_news/forsta-deltagaren-rekryterad-till-den-kliniska-studien-med-mangoral-for-nedsatt-leverfunktion/2020-05-06T08:00:00+02:00https://www.ascelia.com/sv/mfn_news/patent-for-oncoral-godkant-i-japan/2020-04-16T13:45:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-publicerar-arsredovisning-for-rakenskapsaret-2019/2020-04-06T19:00:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharmas-valberedning-foreslar-val-av-lauren-barnes-till-bolagets-styrelse/2020-04-03T10:45:00+02:00https://www.ascelia.com/sv/mfn_news/kallelse-till-arsstamma-i-ascelia-pharma-ab-3/2020-04-03T08:45:00+02:00https://www.ascelia.com/sv/mfn_news/korrektion-till-pressmeddelande-om-andring-av-antalet-aktier-och-roster-i-ascelia-pharma-ab/2020-04-01T17:15:00+02:00https://www.ascelia.com/sv/mfn_news/andring-av-antalet-aktier-och-roster-i-ascelia-pharma-ab-2/2020-03-31T20:15:00+02:00https://www.ascelia.com/sv/mfn_news/att-leda-ascelia-pharma-genom-covid-19-perioden/2020-03-30T15:30:00+02:00https://www.ascelia.com/sv/mfn_news/redeye-ascelia-pharma-framflyttad-position/2020-03-25T08:21:20+01:00https://www.ascelia.com/sv/mfn_news/analysguiden-carlsquare-uppdaterar-sin-bedomning-av-ascelia-pharma-och-hojer-riktkursen-for-aktien/2020-03-05T18:00:00+01:00https://www.ascelia.com/sv/mfn_news/nyemission-och-aterkop-av-c-aktier-for-aktiesparprogram-3/2020-03-02T17:00:00+01:00https://www.ascelia.com/sv/mfn_news/forsta-patienten-rekryterad-till-den-registreringsgrundande-kliniska-fas-iii-studien-sparkle-med-ledande-lakemedelskandidaten-mangoral/2020-02-19T18:30:00+01:00https://www.ascelia.com/sv/mfn_news/bokslutskommunike-2019-kliniker-oppnade-for-rekrytering-till-beslutsgrundande-fas-iii-studien-sparkle/2020-02-14T08:00:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-vinner-priset-som-basta-life-science-bolag-i-malmo/2020-02-11T13:41:31+01:00https://www.ascelia.com/sv/mfn_news/fem-kliniker-ar-nu-oppnade-till-den-registreringsgrundande-kliniska-fas-iii-studien-sparkle-med-ledande-lakemedelskandidaten-mangoral/2020-01-13T15:30:00+01:00https://www.ascelia.com/sv/mfn_news/valberedning-utsedd-infor-arsstamma-2020-i-ascelia-pharma-ab/2019-12-18T09:30:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-utser-julie-waras-brogren-till-chief-commercial-officer/2019-12-06T07:30:00+01:00https://www.ascelia.com/sv/mfn_news/kommunike-fran-arsstamma-den-14-november-2019-i-ascelia-pharma-ab/2019-11-14T14:00:00+01:00https://www.ascelia.com/sv/mfn_news/redeye-ascelia-pharma-q1-ett-kvartal-praglat-av-forberedelser/2019-11-12T08:32:22+01:00https://www.ascelia.com/sv/mfn_news/forberedelser-for-fas-iii-studien-med-mangoral-loper-enligt-plan/2019-11-08T08:00:00+01:00https://www.ascelia.com/sv/mfn_news/forandring-i-ascelia-pharmas-ledningsgrupp/2019-10-25T14:30:00+02:00https://www.ascelia.com/sv/mfn_news/kallelse-till-arsstamma-i-ascelia-pharma-ab-4/2019-10-14T18:10:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-publicerar-arsredovisning-for-rakenskapsaret-2018-2019/2019-10-14T18:00:00+02:00https://www.ascelia.com/sv/mfn_news/redeye-inleder-bevakning-av-ascelia-pharma/2019-10-14T07:53:12+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-presenterar-pa-redeyes-seminarie-i-malmo-den-12e-september-2019/2019-09-11T09:15:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-presenterar-pa-aktiedagen-i-stockholm-den-10e-september-2019/2019-09-06T08:00:00+02:00https://www.ascelia.com/sv/mfn_news/fas-iii-studie-med-mangoral-inleds-h2-2019/2019-08-22T08:00:00+02:00https://www.ascelia.com/sv/mfn_news/inbjudan-till-presentation-av-ascelia-pharmas-q4-rapport-2018-2019/2019-08-20T07:45:00+02:00https://www.ascelia.com/sv/mfn_news/aktiespararnas-vd-poddare-carl-bjartmar-ascelia-pharma/2019-08-08T16:06:32+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-starker-stallningen-for-mangoral-med-en-patentansokan-for-nasta-generations-mangoral-produkt/2019-06-10T07:54:25+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-presenterar-pa-avanza-borsdag-22-maj-2019/2019-05-20T16:00:40+02:00https://www.ascelia.com/sv/mfn_news/fullt-finansierat-fas-iii-program-for-mangoral-genom-borsnoteringen/2019-05-15T08:00:11+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-haller-telekonferens-for-presentation-av-kvartalsrapport/2019-05-13T08:45:00+02:00https://www.ascelia.com/sv/mfn_news/valberedning-utsedd-infor-arsstamma-2019-i-ascelia-pharma-ab/2019-05-10T10:30:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-fick-positiv-feedback-fran-ema-gallande-fas-3-programmet-for-mangoral/2019-05-07T17:50:20+02:00https://www.ascelia.com/sv/mfn_news/andring-av-antalet-aktier-och-roster-i-ascelia-pharma-ab-publ/2019-04-30T14:15:42+02:00https://www.ascelia.com/sv/mfn_news/utnyttjande-av-overtilldelningsoption-meddelande-om-stabiliseringsatgarder-och-avslutande-av-stabiliseringsperiod/2019-04-12T18:37:22+02:00https://www.ascelia.com/sv/mfn_news/meddelande-om-stabiliseringsatgarder/2019-04-11T19:29:30+02:00https://www.ascelia.com/sv/mfn_news/lovande-fas-1-resultat-nar-oncoral-kombineras-med-det-orala-lakemedlet-capecitabin-resultaten-publiceras-i-tidskriften-cancer-chemotherapy-and-pharmacology/2019-04-08T22:33:13+02:00https://www.ascelia.com/sv/mfn_news/meddelande-om-stabiliseringsatgarder-2/2019-04-01T18:44:50+02:00https://www.ascelia.com/sv/mfn_news/andring-av-antalet-aktier-och-roster-i-ascelia-pharma-ab-publ-2/2019-03-29T17:15:03+01:00https://www.ascelia.com/sv/mfn_news/meddelande-om-stabiliseringsatgarder-3/2019-03-21T18:03:07+01:00https://www.ascelia.com/sv/mfn_news/handeln-i-ascelia-pharmas-aktier-pa-nasdaq-stockholm-inleds-imorgon/2019-03-12T17:30:02+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharmas-nyemission-infor-notering-pa-nasdaq-stockholm-blev-vasentligt-overtecknad/2019-03-06T08:05:17+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-offentliggor-prospekt-i-samband-med-borsintroduktion-pa-nasdaq-stockholm/2019-02-20T17:32:22+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-far-positiv-respons-fran-fda-for-utformningen-av-fas-3-studien-av-mangoral/2018-11-19T08:03:54+01:00https://www.ascelia.com/sv/mfn_news/lovande-resultat-fran-oncorals-klinisk-fas-1-studie-presenteras-i-en-ny-publikation/2018-11-13T12:38:11+01:00https://www.ascelia.com/sv/mfn_news/oncoral-visar-lovande-resultat-i-klinisk-fas-1-studie/2018-10-23T13:37:17+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-utser-carl-bjartmar-till-ny-chief-medical-officer/2018-09-14T10:05:50+02:00https://www.ascelia.com/sv/mfn_news/oncorals-fas-1-studier-presenteras-pa-esmo-kongress-i-munchen/2018-09-10T10:00:50+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-har-genomfort-en-nyemission-pa-sek-60-miljoner-for-att-slutfora-fas-3-forberedelserna-for-mangoral/2018-05-16T09:15:00+02:00https://www.ascelia.com/sv/mfn_news/cancerlakemedelsforetaget-ascelia-pharma-forstarker-styrelsen-for-att-stodja-internationell-expansion/2017-11-13T07:53:37+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-starker-produktportfoljen-inom-cancerbehandling/2017-09-14T08:00:00+02:00https://www.ascelia.com/sv/mfn_news/valberedningen-utsedd-i-ascelia-pharma-ab-infor-arsstamman-2023/2022-12-02T17:29:00+01:00https://www.ascelia.com/sv/mfn_news/nya-starka-orviglance-data-stoder-framgangsrik-avslutning-av-sparkle-studien-med-betydligt-farre-patienter/2022-12-07T15:35:06+01:00https://www.ascelia.com/sv/mfn_news/65-patienter-har-slutfort-sparkle-studien/2022-12-29T19:00:00+01:00https://www.ascelia.com/sv/mfn_news/71-patienter-har-slutfort-sparkle-studien/2023-01-27T16:59:00+01:00https://www.ascelia.com/sv/mfn_news/kvartalsrapport-q4-2022-fas-3-studien-for-orviglance-sparkle-forvantas-avslutas-i-forsta-kvartalet-2023/2023-02-10T13:38:06+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-beslutar-om-omvandling-av-c-aktier-till-stamaktier-for-leverans-till-deltagare-i-incitamentsprogram/2023-02-21T20:08:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-nar-viktig-milstolpe-slutfor-patientrekryteringen-till-orviglance-fas-3-studie-sparkle/2023-02-24T07:30:00+01:00https://www.ascelia.com/sv/mfn_news/andring-av-antalet-aktier-och-roster-i-ascelia-pharma-ab-3/2023-02-28T08:00:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-rapporterar-att-den-sista-patientens-sista-besok-lplv-har-genomforts-i-fas-3-studien-sparkle-med-orviglance-vilken-nu-inkluderar-85-patienter-som-slutfort-studien/2023-03-20T19:34:49+01:00https://www.ascelia.com/sv/mfn_news/inbjudan-till-ascelia-pharmas-investeraruppdatering-att-ta-orviglance-till-marknaden-nasta-steg-mot-lansering/2023-03-10T15:16:36+01:00https://www.ascelia.com/sv/mfn_news/ett-tredje-amerikanskt-patentet-starker-patentskyddet-for-ascelia-pharmas-oncoral-daglig-tablett-irinotekan/2023-04-03T08:25:24+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-sorjer-styrelseledamot-rene-spogards-bortgang/2023-04-03T08:25:24+02:00https://www.ascelia.com/sv/mfn_news/valkommen-till-ascelia-pharma-investor-update-att-ta-orviglance-till-marknaden-nasta-steg-mot-lansering/2023-04-03T08:25:24+02:00https://www.ascelia.com/sv/mfn_news/kallelse-till-arsstamma-i-ascelia-pharma-ab-5/2023-04-03T08:00:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-publicerar-arsredovisning-for-2022/2023-04-13T17:00:00+02:00https://www.ascelia.com/sv/mfn_news/rattelse-ascelia-pharma-publicerar-arsredovisning-for-2022/2023-04-13T17:40:00+02:00https://www.ascelia.com/sv/mfn_news/studie-av-nedsatt-leverfunktion-hepatic-impairment-study-accepterad-for-presentation-vid-storre-radiologi-och-leverkonferenser/2023-04-25T07:30:00+02:00https://www.ascelia.com/sv/mfn_news/kommunike-fran-arsstamma-den-4-maj-2023-i-ascelia-pharma-ab/2023-05-04T18:20:00+02:00https://www.ascelia.com/sv/mfn_news/kvartalsrapport-q1-2023-fas-3-studien-for-orviglance-sparkle-sista-patientens-sista-besok-last-patient-last-visit-lplv-har-avslutats/2023-08-04T14:19:49+02:00https://www.ascelia.com/sv/mfn_news/vid-esgars-arsmote-2023-presenterade-ascelia-pharma-orviglance-data-fran-studien-med-nedsatt-leverfunktion-samt-var-vard-for-en-qa-med-experter-inom-leveravbildning/2023-06-16T11:30:00+02:00https://www.ascelia.com/sv/mfn_news/ny-utlasning-kravs-efter-intralasarinkonsistens-rorande-poangsattning-av-bilder-av-lasare-fran-fas-3-studien-sparkle/2023-08-07T23:33:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-ger-fortydliganden-kring-intralasarvariabilitet-vid-utlasningen-av-bilder-i-sparkle-studien/2023-08-10T08:41:55+02:00https://www.ascelia.com/sv/mfn_news/halvarsrapport-2023-ny-utlasning-kravs-efter-intralasarinkonsistens-rorande-poangsattning-av-bilder-av-lasare-fran-fas-3-studien-sparkle/2023-08-30T11:05:02+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-gor-omfattande-neddragning-av-organisationen-for-att-na-headline-resultat-med-sparkle/2023-08-31T10:14:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-nar-headline-resultat-fran-sparkle-utlasningen-i-maj-2024-med-nuvarande-finansiering/2023-09-13T16:00:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-far-oversiktsartikel-om-orviglance-accepterad-for-publicering-i-investigative-radiology/2023-10-04T14:15:00+02:00https://www.ascelia.com/sv/mfn_news/kallelse-till-extra-bolagsstamma-i-ascelia-pharma-ab-2/2023-10-19T18:50:00+02:00https://www.ascelia.com/sv/mfn_news/kvartalsrapport-q3-2023-den-ny-utlasning-av-bilderna-fran-fas-3-studien-sparkle-fortskrider-enligt-planen/2024-01-19T13:26:38+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-beslutar-om-omvandling-av-c-aktier-till-stamaktier-for-leverans-till-deltagare-i-incitaments-program/2023-11-09T13:52:00+01:00https://www.ascelia.com/sv/mfn_news/kommunike-fran-extra-bolagsstamma-den-13-november-2023-i-ascelia-pharma-ab/2023-11-13T17:34:00+01:00https://www.ascelia.com/sv/mfn_news/andring-av-antalet-aktier-och-roster-i-ascelia-pharma-ab-4/2023-11-30T07:30:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-meddelar-start-av-bildlasningsfasen-och-bekraftar-resultat-fran-fas-3-sparkle-senast-i-maj-2024/2024-02-14T13:45:45+01:00https://www.ascelia.com/sv/mfn_news/valberedning-utsedd-i-ascelia-pharma-ab-infor-arsstamman-2024/2024-02-14T13:45:45+01:00https://www.ascelia.com/sv/mfn_news/oversiktsartikel-om-orviglance-publicerad-i-investigative-radiology/2024-02-14T13:45:45+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-sakrar-finansiering-om-upp-till-35-msek/2024-02-14T13:45:44+01:00https://www.ascelia.com/sv/mfn_news/q4-och-bokslutskommunike-2023-starkt-finansiell-position-infor-headline-resultat-i-maj-for-den-kliniska-fas-3-studien-sparkle/2024-02-14T13:45:44+01:00https://www.ascelia.com/sv/mfn_news/kallelse-till-arsstamma-i-ascelia-pharma-ab-6/2024-03-27T07:30:00+01:00https://www.ascelia.com/sv/mfn_news/arsredovisning-2023-solida-framsteg-med-slutford-patientrekrytering-till-orviglance-fas-3-och-forvantat-headline-resultat-i-maj-2024/2024-04-08T17:45:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-rapporterar-att-sparkle-bildlasningsfasen-ar-avslutad-och-forvantar-sig-headline-resultat-i-forsta-halvan-av-maj-2024/2024-04-10T15:04:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-utnyttjar-den-andra-tranchen-om-15-msek-under-befintlig-lanefacilitet/2024-04-18T13:02:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-uppnar-framgangsrikt-det-primara-effektmattet-med-starka-headline-resultat-i-fas-3-studien-med-orviglance/2024-05-02T11:12:00+02:00https://www.ascelia.com/sv/mfn_news/kommunike-fran-arsstamma-den-6-maj-2024-i-ascelia-pharma-ab/2024-05-06T15:10:00+02:00https://www.ascelia.com/sv/mfn_news/valkommen-till-ascelia-pharma-uppdatering-till-investerare-att-fora-orviglance-till-patienterna/2024-05-07T07:31:00+02:00https://www.ascelia.com/sv/mfn_news/kvartalsrapport-q1-primart-effektmatt-uppnatt-med-starka-headline-resultat-i-fas-3-studien-med-orviglance/2024-05-16T07:30:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-genomfor-en-foretradesemission-av-units-om-cirka-105-miljoner-kronor-for-att-fullt-ut-finansiera-inlamnande-av-ansokan-om-marknadsgodkannande-for-orviglance/2024-07-10T17:46:00+02:00https://www.ascelia.com/sv/mfn_news/kallelse-till-extra-bolagsstamma-i-ascelia-pharma-ab-3/2024-07-10T17:50:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-offentliggor-slutliga-villkor-i-foretradesemission/2024-08-09T07:30:00+02:00https://www.ascelia.com/sv/mfn_news/kommunike-fran-extra-bolagsstamma-den-14-augusti-2024-i-ascelia-pharma-ab/2024-08-14T14:35:00+02:00https://www.ascelia.com/sv/mfn_news/halvarsrapport-2024-orviglance-slutfor-den-kliniska-utvecklingen-med-framgangsrik-fas-3-studie/2024-08-15T07:30:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-offentliggor-prospekt-i-samband-med-foretradesemission/2024-08-16T14:44:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-offentliggor-preliminart-utfall-i-foretradesemission/2024-09-04T07:30:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-offentliggor-slutligt-utfall-i-fulltecknad-foretradesemission-om-105-msek/2024-09-05T17:20:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-beslutar-om-en-riktad-emission-av-konvertibler-om-75-msek/2024-09-13T13:25:00+02:00https://www.ascelia.com/sv/mfn_news/andring-av-antalet-aktier-och-roster-i-ascelia-pharma-ab-5/2024-09-30T15:25:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-slutfor-foretradesemission-med-en-forlangd-kassalikviditet-till-sent-2025/2024-09-30T16:50:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-meddelar-att-de-primara-resultaten-fran-sparkle-studien-med-orviglance-accepterats-for-muntlig-presentation-som-cutting-edge-research-vid-rsna-konferensen-2024/2024-10-01T15:35:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-meddelar-forslag-om-val-av-marianne-kock-till-ny-styrelseledamot/2024-10-04T15:25:00+02:00https://www.ascelia.com/sv/mfn_news/kallelse-till-extra-bolagsstamma-i-ascelia-pharma-ab-4/2024-10-04T15:48:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-presenterar-late-breaking-abstract-av-sparkle-data-vid-american-society-of-nephrology-kidney-week-congress-2024/2024-10-24T07:30:00+02:00https://www.ascelia.com/sv/mfn_news/kommunike-fran-extra-bolagsstamma-den-30-oktober-2024-i-ascelia-pharma-ab/2024-10-30T14:45:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-meddelar-att-den-fullstandiga-studierapporten-kompletterats-de-framgangsrika-resultaten-fran-fas-3-studien-sparkle-med-orviglance-starks-ytterligare/2024-11-06T22:40:00+01:00https://www.ascelia.com/sv/mfn_news/kvartalsrapport-q3-framgangsrikt-utfall-av-foretradesemission-om-105-msek-forlanger-kassalikviditeten-till-sent-2025/2024-11-07T07:30:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-beslutar-om-omvandling-av-c-aktier-till-stamaktier-for-leverans-till-deltagare-i-incitamentsprogram-2/2024-11-22T21:05:00+01:00https://www.ascelia.com/sv/mfn_news/andring-av-antalet-aktier-och-roster-i-ascelia-pharma-ab-6/2024-11-29T11:40:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-presenterar-de-primara-resultaten-fran-sparkle-studien-med-orviglance-som-cutting-edge-research-vid-rsna-2024/2024-12-02T16:00:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-meddelar-att-sparkle-data-accepterats-for-presentation-vid-society-of-abdominal-radiology-congress-2025/2024-12-17T15:10:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-patent-for-andra-generationens-orviglance-beviljat-i-kina/2024-12-23T10:02:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-meddelar-att-tre-vetenskapliga-abstracter-med-sparkle-data-accepterats-for-presentation-vid-european-society-of-gastrointestinal-and-abdominal-radiology-annual-meeting/2025-01-27T09:06:56+01:00https://www.ascelia.com/sv/mfn_news/kallelse-till-extra-bolagsstamma-i-ascelia-pharma-ab-5/2025-01-30T13:45:00+01:00https://www.ascelia.com/sv/mfn_news/q4-och-bokslutskommunike-2024-slutforande-av-fullstandig-studierapport-forstarker-framgangsrika-resultat-av-sparkle-fas-3-studien/2025-02-07T07:30:00+01:00https://www.ascelia.com/sv/mfn_news/valberedning-utsedd-i-ascelia-pharma-ab-infor-arsstamman-2025/2025-02-12T21:30:00+01:00https://www.ascelia.com/sv/mfn_news/kommunike-fran-extra-bolagsstamma-den-25-februari-2025-i-ascelia-pharma-ab/2025-02-25T14:45:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-meddelar-positivt-utfall-fran-fda-mote-och-bekraftar-planen-att-insanda-ansokan-om-marknadsgodkannande-nda-for-orviglance-i-mitten-2025/2025-03-18T22:05:00+01:00https://www.ascelia.com/sv/mfn_news/teckningskursen-for-teckningsoptioner-serie-to-1-i-ascelia-pharma-har-faststallts-till-215-sek-och-nyttjandeperioden-inleds-den-1-april-2025/2025-03-31T17:40:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-meddelar-att-studie-av-burden-of-illness-real-world-data-for-orviglance-patientmalgrupp-har-accepterats-for-presentation-vid-ispor-konferensen-2025/2025-04-04T07:30:00+02:00https://www.ascelia.com/sv/mfn_news/kallelse-till-arsstamma-i-ascelia-pharma-ab-7/2025-04-04T13:45:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-meddelar-att-orviglance-studie-publiceras-i-investigative-radiology/2025-04-08T22:00:00+02:00https://www.ascelia.com/sv/mfn_news/arsredovisning-2024-orviglance-gar-vidare-till-registreringsfasen-efter-framgangsrikt-slutforande-av-fas-3-studie/2025-04-11T13:50:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-erhaller-bruttolikvid-om-43-msek-fran-utnyttjande-av-teckningsoptioner-serie-to-1/2025-04-16T17:55:00+02:00https://www.ascelia.com/sv/mfn_news/andring-av-antalet-aktier-och-roster-i-ascelia-pharma-ab-7/2025-04-30T11:30:00+02:00https://www.ascelia.com/sv/mfn_news/kommunike-fran-arsstamma-den-7-maj-2025-i-ascelia-pharma-ab/2025-05-07T16:30:00+02:00https://www.ascelia.com/sv/mfn_news/kvartalsrapport-q1-2025-positivt-utfall-fran-fda-mote-om-orviglance-fore-nda-ansokan/2025-05-16T07:30:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-uppdaterar-tidsplanen-for-nda-ansokan-for-orviglance/2025-08-15T18:25:00+02:00https://www.ascelia.com/sv/mfn_news/halvarsrapport-2025-orviglance-inlamning-av-nda-ansokana-narmar-sig/2025-08-21T07:30:00+02:00https://www.ascelia.com/sv/mfn_news/fenja-capital-ii-a-s-pakallar-konvertering-av-samtliga-utestaende-konvertibler-med-ett-totalt-nominellt-belopp-om-75-msek/2025-09-02T16:10:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-skickar-in-registreringsansokan-nda-for-orviglance-till-den-amerikanska-lakemedelsmyndigheten-fda/2025-09-03T10:10:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-avser-att-genomfora-en-riktad-nyemission-av-aktier-om-cirka-30-msek/2025-09-22T17:36:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-har-genomfort-en-riktad-nyemission-om-cirka-30-msek/2025-09-22T20:55:00+02:00https://www.ascelia.com/sv/mfn_news/andring-av-antalet-aktier-och-roster-i-ascelia-pharma-ab-8/2025-09-30T07:30:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-meddelar-forandringar-i-ledningen-for-att-stodja-framtida-tillvaxt/2025-11-03T09:55:00+01:00https://www.ascelia.com/sv/mfn_news/delarsrapport-q3-2025-orviglance-nda-ansokan-inskickad-till-fda/2025-11-05T07:30:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-insander-ny-patentansokan-for-orviglance/2025-11-10T09:15:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-meddelar-att-fda-har-accepterat-att-granska-ansokan-for-marknadsgodkannande-av-orviglance/2025-11-15T10:15:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-beslutar-om-omvandling-av-c-aktier-till-stamaktier-for-leverans-till-deltagare-i-incitamentsprogram-3/2025-11-19T15:10:00+01:00https://www.ascelia.com/sv/mfn_news/andring-av-antalet-aktier-och-roster-i-ascelia-pharma-ab-9/2025-11-28T15:00:00+01:00https://www.ascelia.com/sv/mfn_news/valberedning-utsedd-i-ascelia-pharma-ab-infor-arsstamman-2026/2025-12-22T07:30:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-meddelar-att-vice-vd-julie-waras-brogren-lamnar-ascelia-pharma/2026-01-21T10:45:00+01:00https://www.ascelia.com/sv/mfn_news/bokslutskommunike-och-q4-2025-fda-accepterar-orviglance-nda-ansokan-for-granskning/2026-02-05T07:30:00+01:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-meddelar-att-orviglance-data-har-accepterats-for-muntlig-presentation-vid-den-arliga-radiologikonferensen-esgar-2026/2026-03-27T14:20:00+01:00https://www.ascelia.com/sv/mfn_news/kallelse-till-arsstamma-i-ascelia-pharma-ab-8/2026-03-30T16:35:00+02:00https://www.ascelia.com/sv/mfn_news/arsredovisning-2025-orviglance-nda-inskickad-till-fda-pdufa-datum-satt-till-juli-2026/2026-04-09T17:00:00+02:00https://www.ascelia.com/sv/mfn_news/ascelia-pharma-genomfor-en-riktad-nyemission-om-20-miljoner-kronor/2026-04-23T21:34:00+02:00https://www.ascelia.com/sv/mfn_news/andring-av-antalet-aktier-och-roster-i-ascelia-pharma-ab-10/2026-04-30T11:00:00+02:00https://www.ascelia.com/sv/mfn_news/kommunike-fran-arsstamma-den-4-maj-2026-i-ascelia-pharma-ab/2026-05-04T16:00:00+02:00